#1 Clinical Trials Search in Europe

3-(2,6-Dichlorophenyl)-2,3-Dihydro-1-Methyl-7-[[3-Methyl-4-(1-Methyl-4-Piperidinyl)Phenyl]Amino]-Pyrimido[4,5-D]Pyrimidin-4(1H)-One

This article discusses the ongoing clinical trials investigating Debio 0123, a highly selective inhibitor of the WEE1 kinase, for the treatment of advanced solid tumors. The trials aim to evaluate the safety, efficacy, and optimal dosing of Debio 0123 alone and in combination with other drugs. These studies focus on patients with specific genetic alterations, including CCNE1 amplification and FBXW7 mutations, and explore the potential of Debio 0123 in various cancer types, including glioblastoma and ovarian cancer.

Table of Contents

What is Debio 0123?

Debio 0123 is an investigational drug being developed for the treatment of various advanced solid tumors. It is classified as a highly selective inhibitor of the WEE1 kinase[1]. The drug is currently being studied in clinical trials to evaluate its safety and effectiveness in treating certain types of cancer.

How Does Debio 0123 Work?

Debio 0123 works by targeting a specific protein in cancer cells called WEE1 kinase. This protein plays a crucial role in regulating the cell cycle, which is the process by which cells grow and divide. By inhibiting WEE1 kinase, Debio 0123 aims to disrupt the cancer cells’ ability to repair DNA damage and divide properly, potentially leading to their death[1].

What Conditions Does Debio 0123 Treat?

Debio 0123 is being investigated for the treatment of various advanced solid tumors, particularly those with specific genetic characteristics. The clinical trials are focusing on patients with:

  • Glioblastoma (GBM): A type of aggressive brain cancer[1]
  • Advanced solid tumors with specific genetic alterations, including:
    • CCNE1 amplification
    • Deleterious mutations in FBXW7
    • Other proprietary gene mutations[2]
  • High-grade serous ovarian, fallopian tube, or primary peritoneal cancer[2]

Clinical Trials and Research

Debio 0123 is currently being studied in several clinical trials:

  1. Glioblastoma Study: A phase 1/2 trial is investigating Debio 0123 in combination with temozolomide (TMZ) for patients with recurrent or newly diagnosed glioblastoma[1]. This study aims to:
    • Determine the safety and tolerability of the combination
    • Find the appropriate dose for further investigation
    • Assess the drug’s effectiveness against glioblastoma
  2. Advanced Solid Tumors Study (MYTHIC): A phase 1/1b trial is examining Debio 0123 alone and in combination with other drugs for patients with advanced solid tumors[2]. This study focuses on:
    • Evaluating the safety and tolerability of Debio 0123
    • Determining the best dose and schedule for treatment
    • Assessing the drug’s effectiveness against various types of solid tumors

Administration and Dosage

Debio 0123 is administered orally in the form of hard capsules[1][2]. The exact dosage and schedule are still being determined through the ongoing clinical trials. Patients participating in these studies will receive specific instructions from their healthcare providers regarding how and when to take the medication.

Potential Side Effects

As Debio 0123 is still in the investigational stage, the full range of potential side effects is not yet known. The clinical trials are designed to assess the safety profile of the drug and identify any adverse events. Some general side effects that are being monitored include:

  • Changes in blood cell counts
  • Liver function abnormalities
  • Gastrointestinal issues
  • Fatigue
  • Potential effects on heart rhythm (QT interval prolongation)[2]

It’s important to note that patients participating in clinical trials are closely monitored for any side effects, and the researchers take necessary precautions to ensure patient safety.

Conclusion

Debio 0123 represents a promising new approach in the treatment of advanced solid tumors, particularly those with specific genetic characteristics. While still in the investigational stage, the ongoing clinical trials aim to establish its safety and efficacy. Patients with eligible conditions who have exhausted standard treatment options may want to discuss with their oncologists whether participating in a clinical trial involving Debio 0123 could be appropriate for their situation.

Aspect Details
Drug Name Debio 0123
Drug Type Highly selective inhibitor of the WEE1 kinase
Administration Oral (hard capsules)
Target Conditions Advanced solid tumors, glioblastoma, high-grade serous ovarian cancer
Genetic Targets CCNE1 amplification, FBXW7 mutations, PPP2R1A mutations
Trial Phases Phase 1/1b and Phase 2
Key Objectives Safety, tolerability, optimal dosing, pharmacokinetics, preliminary efficacy
Combination Therapies Temozolomide, RP-3500
Patient Age Range 12 years and older (varies by trial module)
Primary Endpoints Adverse events, dose-limiting toxicities, pharmacokinetics, tumor response

FAQ

  • What is Debio 0123? Debio 0123 is a highly selective inhibitor of the WEE1 kinase. It is being studied as a potential treatment for advanced solid tumors, particularly in patients with specific genetic alterations such as CCNE1 amplification or FBXW7 mutations.
  • What types of cancer are being studied in these clinical trials? The clinical trials are focusing on various advanced solid tumors, including glioblastoma (a type of brain cancer) and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The studies also include patients with other types of solid tumors that have specific genetic alterations.
  • How is Debio 0123 being administered in these trials? Debio 0123 is being administered orally in the form of hard capsules. The trials are exploring its use both as a single agent and in combination with other drugs, such as temozolomide (for glioblastoma) and RP-3500.
  • What are the main objectives of these clinical trials? The main objectives of these trials are to assess the safety and tolerability of Debio 0123, determine the optimal dosing, evaluate its pharmacokinetics (how the drug moves through the body), and assess its preliminary anti-tumor activity in patients with advanced solid tumors.
  • Who is eligible to participate in these clinical trials? Eligibility varies depending on the specific trial module, but generally includes patients aged 12 and older with advanced solid tumors that have specific genetic alterations. Patients must have adequate organ function and meet certain health criteria. Some trials are specifically for adults with recurrent glioblastoma or newly diagnosed glioblastoma, while others focus on ovarian cancer patients who have received prior treatment.

Ongoing Clinical Trials on 3-(2,6-Dichlorophenyl)-2,3-Dihydro-1-Methyl-7-[[3-Methyl-4-(1-Methyl-4-Piperidinyl)Phenyl]Amino]-Pyrimido[4,5-D]Pyrimidin-4(1H)-One

  • Study on the Safety of RP-6306 Alone or with RP-3500 or Debio 0123 for Patients with Advanced Solid Tumors

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark France The Netherlands Spain

  • Study of Debio 0123 and Temozolomide for Adults with Recurrent or Newly Diagnosed Glioblastoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • WEE1 kinase: An enzyme that plays a crucial role in regulating cell division. Inhibiting WEE1 can potentially disrupt cancer cell growth.
  • CCNE1 amplification: An increase in the number of copies of the CCNE1 gene, which is associated with certain types of cancer and may affect treatment response.
  • FBXW7 mutations: Changes in the FBXW7 gene, which can lead to abnormal cell growth and are found in some cancers.
  • Glioblastoma: An aggressive type of cancer that occurs in the brain or spinal cord.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Dose-limiting toxicity (DLT): Side effects of a treatment that are severe enough to prevent an increase in dosage or require a reduction in dosage.
  • Maximum tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Recommended Phase 2 dose (RP2D): The dose of a drug recommended for further testing in Phase 2 clinical trials, based on safety and efficacy data from Phase 1 trials.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.

References

  1. http://clinicaltrials.eu/trial/study-of-debio-0123-and-temozolomide-for-adults-with-recurrent-or-newly-diagnosed-glioblastoma/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-of-rp-6306-alone-or-with-rp-3500-or-debio-0123-for-patients-with-advanced-solid-tumors/